Literature DB >> 23696021

Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer.

Kejin Wu1, Shuo Huang, Mingjie Zhu, Yunshu Lu, Jian Chen, Yongkun Wang, Qing Lin, Wei Shen, Shenglai Zhang, Jian Zhu, Y Eric Shi, Ziyi Weng.   

Abstract

Synuclein gamma (SNCG), previously identified as breast cancer-specific gene 1, is highly expressed in malignant cells but not in normal epithelium. Studies have demonstrated that the expression of SNCG is an independent predictive marker for recurrence and metastasis in breast cancer. Triple-negative breast cancer (TNBC) is characterized by a lack of expression of both the estrogen receptor and progesterone receptor proteins as well as HER-2 and is often associated with particularly poor outcomes, early development of chemotherapy resistance, and ineffectiveness of targeted therapy. This study aimed to reveal whether SNCG-positive TNBC is more likely than SNCG-negative TNBC to have a more aggressive phenotype. One hundred and two TNBC patients were divided into two groups according to the SNCG protein expression. Clinical and biological features of SNCG-positive tumors were compared with SNCG-negative tumors. Association between survival and SNCG expression was analyzed by the Kaplan-Meier method. Hazard ratios and 95 % confidence intervals (CIs) were calculated using Cox regression. And 34.3 % TNBCs showed moderate to strong positive SNCG expression. Patients whose tumors expressed SNCG had significantly shorter disease-free survival (P = 0.013) and a higher probability of death (P = 0.002) when compared with those whose tumors did not express SNCG. The hazard ratio of metastasis or recurrence based on SNCG expression status was 2.800 (95 % CI 1.193-6.574; P = 0. 018). There was no significant correlation between SNCG expression and age, lymph node involvement, and tumor stage histological type, except tumor size which was significantly associated with SNCG expression (P = 0.032, R = 0.212). This study suggests that SNCG expression indicates [Symbol: see text]correlates with?[Symbol: see text] a much poorer prognosis of TNBC. SNCG is expected to be a useful marker for TNBC progression and a potential target for TNBC treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23696021     DOI: 10.1007/s12032-013-0612-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  The reciprocal regulation of gamma-synuclein and IGF-I receptor expression creates a circuit that modulates IGF-I signaling.

Authors:  Minjing Li; Yancun Yin; Hui Hua; Xiangming Sun; Ting Luo; Jiao Wang; Yangfu Jiang
Journal:  J Biol Chem       Date:  2010-07-29       Impact factor: 5.157

2.  Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.

Authors:  Kejin Wu; Zhiwei Quan; Ziyi Weng; Fangming Li; Yichu Zhang; Xiaohong Yao; Yiding Chen; Daniel Budman; Itzhak D Goldberg; Y Eric Shi
Journal:  Breast Cancer Res Treat       Date:  2006-07-04       Impact factor: 4.872

3.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

4.  The prognostic importance of triple negative breast carcinoma.

Authors:  Hakan Mersin; Emin Yildirim; Ugur Berberoglu; Kaptan Gülben
Journal:  Breast       Date:  2008-05-01       Impact factor: 4.380

5.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

6.  Stimulation of breast cancer invasion and metastasis by synuclein gamma.

Authors:  T Jia; Y E Liu; J Liu; Y E Shi
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

7.  Stage-specific expression of breast cancer-specific gene gamma-synuclein.

Authors:  Kejin Wu; Ziyi Weng; Qinghua Tao; Gufa Lin; Xiangru Wu; Huiqin Qian; Yichu Zhang; Xiaoyan Ding; Yangfu Jiang; Yuenian Eric Shi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-09       Impact factor: 4.254

8.  Stimulation of estrogen receptor signaling by gamma synuclein.

Authors:  Yangfu Jiang; Yiliang Ellie Liu; AiPing Lu; Anu Gupta; Itzhak D Goldberg; Jingwen Liu; Y Eric Shi
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

9.  Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells.

Authors:  Irina G Surgucheva; Jeremy M Sivak; M Elizabeth Fini; Robert E Palazzo; Andrei P Surguchov
Journal:  Arch Biochem Biophys       Date:  2003-02-01       Impact factor: 4.013

10.  The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

Authors:  Jiyoung Rhee; Sae-Won Han; Do-Youn Oh; Jee Hyun Kim; Seock-Ah Im; Wonshik Han; In Ae Park; Dong-Young Noh; Yung-Jue Bang; Tae-You Kim
Journal:  BMC Cancer       Date:  2008-10-23       Impact factor: 4.430

View more
  6 in total

1.  Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Abigail D Winder; Kruti P Maniar; Jian-Jun Wei; Dachao Liu; Denise M Scholtens; John R Lurain; Julian C Schink; Barbara M Buttin; Virginia L Filiaci; Heather A Lankes; Nilsa C Ramirez; Kay Park; Meenakshi Singh; Richard W Lieberman; Robert S Mannel; Matthew A Powell; Floor J Backes; Cara A Mathews; Michael L Pearl; Angeles Alvarez Secord; David J Peace; David G Mutch; William T Creasman; J Julie Kim
Journal:  Cancer       Date:  2016-12-07       Impact factor: 6.860

Review 2.  The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.

Authors:  Qingli Jiao; Aiguo Wu; Guoli Shao; Haoyu Peng; Mengchuan Wang; Shufeng Ji; Peng Liu; Jian Zhang
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

3.  The Breast Cancer Susceptibility Gene Product (γ-Synuclein) Alters Cell Behavior through its [corrected] Interaction with Phospholipase Cβ.

Authors:  V Siddartha Yerramilli; Suzanne Scarlata
Journal:  Cell Signal       Date:  2015-10-28       Impact factor: 4.315

4.  Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients.

Authors:  Didem Tastekin; Suleyman Kargin; Mehmet Karabulut; Naile Yaldız; Makbule Tambas; Necla Gurdal; Ali Murat Tatli; Deniz Arslan; Ali Fuat Kaan Gok; Faruk Aykan
Journal:  Tumour Biol       Date:  2014-08-21

5.  Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry.

Authors:  Jiyu Zhao; Nianzeng Xing
Journal:  Med Sci Monit       Date:  2014-12-05

6.  Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway.

Authors:  Yiqin Ge; Kan Xu
Journal:  Cancer Cell Int       Date:  2016-11-15       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.